---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-015343"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T09:03:14.801206+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS

## Summary
- ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.
- Dravet patients: median convulsive seizure reduction -33.7% (wk1-12), -47.8% (wk49-60), -58.2% (wk97-108).
- LGS patients: median drop seizure reduction -29.3% (wk1-12), -14.1% (wk49-60), -36.6% (wk97-108).
- Post-hoc ELEKTRA analysis: soticlestat showed numerically superior reduction vs placebo across most seizure types.
- Ovid maintains significant financial interest in soticlestat (milestones and royalties from Takeda).

## SEC filing metadata
- accession: 0000950170-23-015343
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/0000950170-23-015343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017023015343/ovid-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-015343
- JSON: https://secwatch.observer/filing/0000950170-23-015343.json
- Plain text: https://secwatch.observer/filing/0000950170-23-015343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.